Avacopan yields strong safety profile in ANCA-associated vasculitis
Patients who receive avacopan for antineutrophil cytoplasmic antibody-associated vasculitis demonstrate fewer infections and serious adverse events vs. non-avacopan treatment, according to a post-hoc analysis of three trials.“It is always important to provide patients and clinicians with as much information as possible about the safety of new medications,” Peter A. Merkel, MD, MPH,